Skip to main content
Menu

Posts tagged with "Press Coverage"

  • Press Coverage

    The New York TImes on Drug Discovery

    The New York Times Magazine has a piece on the current problems with drug discovery. I was interviewed by the author, and get I quoted at one point. Nothing in the article will amaze any regular reader here, but it’s probably the first time many of the magazine’s readership are hearing about many of these… Read More
  • Clinical Trials

    Studies Show? Not So Fast.

    Yesterday’s post on yet another possible Alzheimer’s blood test illustrates, yet again, that understanding statistics is not a strength of most headline writers (or most headline readers). I’m no statistician myself, but I have a healthy mistrust of numbers, since I deal with the little rotters all day long in one form or another. Read More
  • Cancer

    Is Palbociclib Promising? Or Not?

    Here’s a good test for whatever news outlets you might be using for biotech information. How are they handling Pfizer’s release of palbociclib information from the AACR meeting over the weekend? Do a news search for the drug’s name, and you’ll see headline after headline. Many of them include the phrase “Promising Resu… Read More
  • Cancer

    For Immediate Rewording. Uh, Release.

    Here’s a nice look at why you should always think about the source of the financial and business information you read. It details the response to a recent Pfizer press release about palbociclib, a CDK inhibitor that’s in late clinical trials. Someone at The Wall Street Journal wrote that it had “the potential. . .to… Read More
  • Chemical News

    The West Virginia Formaldehyde Claim Is Nonsense

    This morning I heard reports of formaldehyde being found in Charleston, West Virginia water samples as a result of the recent chemical spill there. My first thought, as a chemist, was “You know, that doesn’t make any sense”. A closer look confirmed that view, and led me to even more dubious things about this news… Read More
  • Chemical News

    A Long Fight Over Allegations of Fraud

    Here’s a long article from the Raleigh News and Observer (part one and part two) on the Eaton/Feldheim/Franzen dispute in nanoparticles, which some readers may already be familiar with (I haven’t covered it on the blog myself). The articles are clearly driven by Franzen’s continued belief that research fraud has been committed, an… Read More
  • Press Coverage

    More Worthless Press Releases

    To go along with those nominations for worst press releases of the year, here’s a roundup of stinkers in the biomedical field. And they do reek. I got some of these in my in-box as well, and I probably got even more of them than I remember. Sad to say, PR material (or at least… Read More
  • Press Coverage

    Worst Scientific Press Releases of 2013?

    In the same spirit as Adam Feuerstein’s “Worst Biotech CEO” nominations from the other day, here’s Michael Eisen asking what the worst scientific press releases of the year were. Most Overhyped and Most Egregious Failure to Cite Earlier Work are two especially hard categories to win. If you have some examples that particular… Read More
  • Press Coverage

    An Alzheimer’s Cure? Not So Fast.

    The British press (and to a lesser extent, the US one) was full of reports the other day about some startling breakthrough in Alzheimer’s research. We could certainly use one, but is this it? What would an Alzheimer’s breakthrough look like, anyway? Given the complexity of the disease, and the difficulty of extrapolating from its… Read More
  • Cancer

    Overselling p53 Drugs

    You may have seen some “wonder drug” news stories over the holiday break about compounds targeting p53 – many outlets picked up this New York Times story. The first paragraph probably got them: For the first time ever, three pharmaceutical companies are poised to test whether new drugs can work against a wide range of… Read More
...345...